Before comparing prices it is worth knowing what is actually on offer, because the answer is narrower than the marketing suggests. Two products account for most of this market, and the alternative a buyer is most likely to ask for — a tablet — is both scarce and dearer, which is the finding set out at length in the tablet costs more.
What the corpus looks like
Across 962 priced rows, injected semaglutide accounts for 432 and injected tirzepatide 394. Together that is 86% of everything this site tracks. The remaining rows divide between oral formulations and a small number of other molecules.
⛔ These are rows, not companies. A seller publishing four figures appears four times, which is the right unit for asking how much of this market is a given product and the wrong one for asking how many businesses sell it.
What barely exists yet
Newer molecules appear in single figures. That is a fact about this roster in September 2026 rather than a judgment about the drugs — the trial evidence behind the newest oral is recent and substantial, and its absence here reflects how long it takes a compounded market to reach a molecule rather than anything about whether it works.
It does mean that a reader who has read about a new drug and gone looking for it will mostly find the same two injections under different brand names. Which of those two is worth paying more for is the question in what the tirzepatide premium buys.
Why the concentration matters to a price
A market where 86% of the rows are two products is a market where differentiation has to come from somewhere other than the molecule. It comes from price, from what is bundled into it, and from what the seller will tell you — which is why this site measures those three things rather than the drug.
It also means the spread between sellers offering the identical product is the number worth looking at, and that spread is wide. The full arithmetic is in what a GLP-1 actually costs, and the fees that sit outside it in the gap between what is shown and what is billed.